Promising strategies have emerged, including FAP-activated prodrugs that selectively target tumour stroma, inhibition of specific signalling pathways involved in CAF-cancer cell crosstalk, and repurposing existing drugs like losartan for modulating the tumour microenvironment. This evidence concerns the gene FAP and cancer.